Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2025-866/coif). S.M.R. reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Pfizer, AZ, Pierre-Fabre, Sanofi, BMS, Takeda, Novartis, Lilly, and Regeneron; and support for attending meetings and/or travel: Roche, Lilly, Merck, Pfizer, BMS, Novartis, MSD, Lilly, Pierre-Fabre, and Janssen. A.B. reports Astrazeneca advisory board and invited speaker, BMS expert testimony and invited speaker, Jansenn congress funding, MSD invited speaker, Novartis invited speaker, Pfizer invited speaker and congress funding, Piere Fabre invited speaker and congress funding, Regeneron invited speaker, Roche invited speaker and advisory board, Sanofy advisory board and invited speaker; BMS Principal Investigator, Clinical Trial CA224-1044; Dizal Prinpial Investigator DZ2022E0005 & DZ2019E0001; and Pfizer Principal Investigator, Clinical Trial C4221016. M.M. reports advisory board, consulting fees or invited speaker: Amgen, AstraZeneca, Boehringer Ingelheim, BeOne, Bristol-Myers Squibb, Helsinn Therapeutics, Johnson & Johnson, MSD, Novartis, Pfizer, Pharmamar, F. Hoffmann-La Roche Ltd., Takeda, Sanofi, Johnson & Johnson, Regeneron, Cassen Recordatti, and Immedica; research funding (institution): Bristol-Myers Squibb, AstraZeneca, and F. Hoffmann-La Roche Ltd.; and travel and accommodation support: AstraZeneca, F. Hoffmann-La Roche Ltd., Pfizer, and MSD. The other authors have no conflicts of interest to declare.